Catalog No.: PC-25522Not For Human Use, Lab Use Only.
TAK-593 is a potent, selective and ATP-competitive inhibitor of tyrosine kinases VEGFR and PDGFR with IC50s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.
TAK-593 is a potent, selective and ATP-competitive inhibitor of tyrosine kinases VEGFR and PDGFR with IC50s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively. TAK-593 strongly suppresses proliferation of VEGF-stimulated human umbilical vein endothelial cells with an IC50 of 0.30 nM。 TAK-593 potently inhibits VEGF- and PDGF-stimulated cellular phosphorylation and proliferation of human umbilical vein endothelial cells and human coronary artery smooth muscle cells. TAK-593 exhibits strong anti-tumor effects against various human cancer xenografts. TAK-593 shows anti-proliferative and pro-apoptotic effects on tumors along with a decrease of vessel density and inhibition of pericyte recruitment to microvessels in vivo.
